Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Henry Meds vs Independent Wellness

Two GLP-1 desks, one scoreboard. We put Henry Meds and Independent Wellness head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 31 · Grade B

Henry Meds

Visit Henry Meds Full brief →
vs
No. 48 · Grade B−

Independent Wellness

Visit Independent Wellness Full brief →

The verdict

Henry Meds takes this head-to-head.

Henry Meds scores 84 to 80 on our six-factor Brief Score — A flat-fee compounded pioneer — simple model, but its price has drifted to the higher end of our ranking.

That doesn't make Independent Wellness a bad call — it's best for readers who want mainstream telehealth glp-1 access. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
78
Supply Reliability
84
74
Transparency
85
88
Access Breadth
82
90
Clinical Oversight
84
74
Track Record
85
73
Henry MedsBrief Score 84 · 80Independent Wellness

Price, coverage & the tracker

Henry MedsIndependent Wellness
Brief Score84/100 (B)80/100 (B−)
Semaglutide$249/moFrom $249/mo (all doses, compounded)
Tirzepatide$349/moFrom $379/mo (all doses, compounded)
CoverageMulti-stateAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerRisingprice risingNewnew to the tracker, no prior reading

Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.

Independent Wellness: New to the tracker on 1 August 2026. The published line reads From $249/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.